GRAIL, Inc. - Common Stock (GRAL)

50.21
-51.32 (-50.55%)
NASDAQ · Last Trade: Feb 20th, 4:38 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Grail, Inc. (NASDAQ: GRAL). The investigation focuses on Grail’s executive officers and whether investor losses may be recovered under federal securities laws.
By Johnson Fistel, PLLP · Via Business Wire · February 19, 2026
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences.
Via MarketBeat · July 16, 2024